ClinicalTrials.gg
CompletedNCT05067270Updated Oct 4, 2023Results posted

A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus

A Phase 1 interventional study of Sodium Citrate and Treprostinil in Type 1 Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 2 sites in Germany. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2023-10-04.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company — 4 open to participants now, 6 under way, 4 of them phase 3. Diabetes Mellitus, Type 1 · Eli Lilly and Company.

Enrollment
41st of 72
40 · median 62
Started
2021
with 1 other
Phase 1
33 of 75
2 open now
Registered
64th of 75
by date

Among the 75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company, this one is the 41st largest by enrollment of the 72 interventional ones that give a count, is one of 2 that started in 2021, is one of 33 in phase 1, and was the 64th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

4 of the 75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 69 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the effect of excipients sodium citrate and treprostinil without insulin on local infusion site pain in participants with type 1 diabetes mellitus (T1DM) on continuous subcutaneous insulin infusion (CSII). The study may last up to 36 days including a screening period and 3 visits.

03

Conditions studied

  • Type 1 Diabetes Mellitus

Keywords

  • Humalog - Insulin lispro
  • Citrate
  • Infusion Site Pain
  • Excipients
04

Who can participate

Ages eligible
18 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • T1D for at least 1 year and continuously using insulin for at least 1 year
  • Using an insulin pump for at least the last 6 months
  • Have (HbA1c) value of ≤ 9.0%
  • Have a (BMI) within the range of 18.5 to 35.0 kilograms per square meter (kg/m²)
  • Have medical and laboratory test results that are acceptable for the study
  • Have venous access sufficient to allow for blood sampling

Exclusion criteria

Exclusion Criteria:

  • Hemophilia or any other bleeding disorder
  • Have a pathologic tuning fork test as assessed with a Rydel-Seiffer tuning fork
  • Are taking anesthetics or pain medication regularly or intermittently which could interfere with interpretation of pain scale
  • Have had more than 1 episode of severe hypoglycemia (defined as requiring assistance due to neurologically disabling hypoglycemia) within the last 90 days prior to screening
  • Have had more than 1 emergency room visit or hospitalization due to poor glucose control (hyperglycemia or diabetic ketoacidosis) within the last 6 months prior to screening
  • Have any or allergy to any of the diluents or used in this trial
  • Have or used to have health problems or medical test results that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study
  • Have participated, within the last 30 days, in a clinical trial involving an product
  • Have used or are currently using Lyumjev® as part of their standard insulin therapy
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Sequence 1:Arm Region,Abdomen 6mm,Buttock,Abdomen 9mm,Thigh

    Participants had cannulas inserted into each of the designated infusion sites (6 millimeter (mm) for all the sites. Additionally for the abdominal area only, a 9 mm cannula was also inserted into the opposite side of the lower abdomen), and the first infusion site was initiated subcutaneously (SC) with 15 millimolar (mM) sodium citrate and 1 microgram per milliliter (μg/mL) treprostinil in Humalog diluent with 5 mM magnesium chloride (without insulin) solution at a basal infusion rate of 1 unit per hour (U/h). The same procedure occurred at subsequent infusion sites with an approximately 30-minute (min) interval between each initiation. Approximately 3, 6, and 9 hours after the start of the basal infusion, a bolus dose of 15 U was delivered at quick bolus speed (15 U/min) to each infusion site according to the treatment sequence with an approximately 30-minute interval between infusion sites.

    Drug: Sodium Citrate · Drug: Treprostinil · Drug: Humalog diluent · Drug: Magnesium Chloride

  • Experimental
    Sequence 2:Abdomen 6mm,Abdomen 9mm,Arm Region,Thigh,Buttock

    Participants had cannulas inserted into each of the designated infusion sites (6 mm for all the sites. Additionally for the abdominal area only, a 9 mm cannula was also inserted into the opposite side of the lower abdomen), and the first infusion site was initiated with 15 mM sodium citrate and 1 μg/mL treprostinil in Humalog diluent with 5 mM magnesium chloride (without insulin) solution at a basal infusion rate of 1 U/h. The same procedure occurred at subsequent infusion sites with an approximately 30-minute interval between each initiation. Approximately 3, 6, and 9 hours after the start of the basal infusion, a bolus dose of 15 U was delivered at quick bolus speed (15 U/min) to each infusion site according to the treatment sequence with an approximately 30-minute interval between infusion sites.

    Drug: Sodium Citrate · Drug: Treprostinil · Drug: Humalog diluent · Drug: Magnesium Chloride

  • Experimental
    Sequence 3:Abdomen 9mm,Thigh,Abdomen 6mm,Buttock,Arm Region

    Participants had cannulas inserted into each of the designated infusion sites (6 mm for all the sites. Additionally for the abdominal area only, a 9 mm cannula was also inserted into the opposite side of the lower abdomen), and the first infusion site was initiated with 15 mM sodium citrate and 1 μg/mL treprostinil in Humalog diluent with 5 mM magnesium chloride (without insulin) solution at a basal infusion rate of 1 U/h. The same procedure occurred at subsequent infusion sites with an approximately 30-minute interval between each initiation. Approximately 3, 6, and 9 hours after the start of the basal infusion, a bolus dose of 15 U was delivered at quick bolus speed (15 U/min) to each infusion site according to the treatment sequence with an approximately 30-minute interval between infusion sites.

    Drug: Sodium Citrate · Drug: Treprostinil · Drug: Humalog diluent · Drug: Magnesium Chloride

  • Experimental
    Sequence 4:Thigh,Buttock,Abdomen 9mm,Arm Region,Abdomen 6mm

    Participants had cannulas inserted into each of the designated infusion sites (6 mm for all the sites. Additionally for the abdominal area only, a 9 mm cannula was also inserted into the opposite side of the lower abdomen), and the first infusion site was initiated with 15 mM sodium citrate and 1 μg/mL treprostinil in Humalog diluent with 5 mM magnesium chloride (without insulin) solution at a basal infusion rate of 1 units per U/h. The same procedure occurred at subsequent infusion sites with an approximately 30-minute interval between each initiation. Approximately 3, 6, and 9 hours after the start of the basal infusion, a bolus dose of 15 U was delivered at quick bolus speed (15 U/min) to each infusion site according to the treatment sequence with an approximately 30-minute interval between infusion sites.

    Drug: Sodium Citrate · Drug: Treprostinil · Drug: Humalog diluent · Drug: Magnesium Chloride

  • Experimental
    Sequence 5:Buttock,Arm Region,Thigh,Abdomen 6mm,Abdomen 9mm

    Participants had cannulas inserted into each of the designated infusion sites (6 mm for all the sites. Additionally for the abdominal area only, a 9 mm cannula was also inserted into the opposite side of the lower abdomen), and the first infusion site was initiated with 15 mM sodium citrate and 1 μg/mL treprostinil in Humalog diluent with 5 mM magnesium chloride (without insulin) solution at a basal infusion rate of 1 U/h. The same procedure occurred at subsequent infusion sites with an approximately 30-minute interval between each initiation. Approximately 3, 6, and 9 hours after the start of the basal infusion, a bolus dose of 15 U was delivered at quick bolus speed (15 U/min) to each infusion site according to the treatment sequence with an approximately 30-minute interval between infusion sites.

    Drug: Sodium Citrate · Drug: Treprostinil · Drug: Humalog diluent · Drug: Magnesium Chloride

Interventions

06

What researchers measure

Primary outcomes

  1. Visual Analog Scale (VAS) Pain Score in the Abdominal, Arm, Thigh, and Buttock Areas

    The Infusion site pain VAS score is a participant administered single item scale designed to measure pain using a 0-100 millimeter (mm) horizontal VAS. Overall severity of participant's pain is indicated by placing a single mark on the horizontal 100 mm scale from 0 mm (no pain) to 100 mm (worst imaginable pain).

    Time frame: Day 1: 1 min post bolus.

07

Results

Posted Oct 4, 2023

Participant flow

Participants were randomly assigned to 1 of 5 infusion site sequence below and received the study treatment in each period. Cannulas were inserted into each of the designated infusion sites (6 millimeter (mm) for all the sites. Additionally for the abdominal area only, a 9 mm cannula was also inserted into the opposite side of the lower abdomen).

Period 1
Participant flow — Period 1
MilestoneSequence 1:Arm Region,Abdomen 6mm,Buttock,Abdomen 9mm,ThighSequence 2:Abdomen 6mm,Abdomen 9mm,Arm Region,Thigh,ButtockSequence 3:Abdomen 9mm,Thigh,Abdomen 6mm,Buttock,Arm RegionSequence 4:Thigh,Buttock,Abdomen 9mm,Arm Region,Abdomen 6mmSequence 5:Buttock,Arm Region,Thigh,Abdomen 6mm,Abdomen 9mm
Started88888
Received at least one infusion88888
Completed88888
Not completed00000
Period 2
Participant flow — Period 2
MilestoneSequence 1:Arm Region,Abdomen 6mm,Buttock,Abdomen 9mm,ThighSequence 2:Abdomen 6mm,Abdomen 9mm,Arm Region,Thigh,ButtockSequence 3:Abdomen 9mm,Thigh,Abdomen 6mm,Buttock,Arm RegionSequence 4:Thigh,Buttock,Abdomen 9mm,Arm Region,Abdomen 6mmSequence 5:Buttock,Arm Region,Thigh,Abdomen 6mm,Abdomen 9mm
Started88888
Received at least one infusion88888
Completed88888
Not completed00000
Period 3
Participant flow — Period 3
MilestoneSequence 1:Arm Region,Abdomen 6mm,Buttock,Abdomen 9mm,ThighSequence 2:Abdomen 6mm,Abdomen 9mm,Arm Region,Thigh,ButtockSequence 3:Abdomen 9mm,Thigh,Abdomen 6mm,Buttock,Arm RegionSequence 4:Thigh,Buttock,Abdomen 9mm,Arm Region,Abdomen 6mmSequence 5:Buttock,Arm Region,Thigh,Abdomen 6mm,Abdomen 9mm
Started88888
Received at least one infusion88888
Completed88888
Not completed00000
Period 4
Participant flow — Period 4
MilestoneSequence 1:Arm Region,Abdomen 6mm,Buttock,Abdomen 9mm,ThighSequence 2:Abdomen 6mm,Abdomen 9mm,Arm Region,Thigh,ButtockSequence 3:Abdomen 9mm,Thigh,Abdomen 6mm,Buttock,Arm RegionSequence 4:Thigh,Buttock,Abdomen 9mm,Arm Region,Abdomen 6mmSequence 5:Buttock,Arm Region,Thigh,Abdomen 6mm,Abdomen 9mm
Started88888
Received at least one infusion88888
Completed88888
Not completed00000
Period 5
Participant flow — Period 5
MilestoneSequence 1:Arm Region,Abdomen 6mm,Buttock,Abdomen 9mm,ThighSequence 2:Abdomen 6mm,Abdomen 9mm,Arm Region,Thigh,ButtockSequence 3:Abdomen 9mm,Thigh,Abdomen 6mm,Buttock,Arm RegionSequence 4:Thigh,Buttock,Abdomen 9mm,Arm Region,Abdomen 6mmSequence 5:Buttock,Arm Region,Thigh,Abdomen 6mm,Abdomen 9mm
Started88888
Received at least one infusion88888
Completed88888
Not completed00000

Outcome measures

PrimaryVisual Analog Scale (VAS) Pain Score in the Abdominal, Arm, Thigh, and Buttock Areas

The Infusion site pain VAS score is a participant administered single item scale designed to measure pain using a 0-100 millimeter (mm) horizontal VAS. Overall severity of participant's pain is indicated by placing a single mark on the horizontal 100 mm scale from 0 mm (no pain) to 100 mm (worst imaginable pain).

Time frame:
Day 1: 1 min post bolus.
Reported as:
Geometric mean · millimeter
Visual Analog Scale (VAS) Pain Score in the Abdominal, Arm, Thigh, and Buttock Areas
millimeterTreatment Given to Arm RegionTreatment Given to ThighTreatment Given to Abdomen (6 mm)Treatment Given to Abdomen (9 mm)Treatment Given to Buttock
1 min post bolus (Bolus time: 3 hours)3.4 ± 1822.0 ± 1191.8 ± 1121.9 ± 1192.4 ± 167
1 min post bolus (Bolus time: 6 hours)3.7 ± 1642.6 ± 1372.3 ± 1512.0 ± 1133.3 ± 161
1 min post bolus (Bolus time: 9 hours)4.8 ± 2113.4 ± 1552.5 ± 1412.4 ± 1413.8 ± 196
Statistical analysis
  • Treatment Given to Arm Region vs Treatment Given to Thigh · Geometric least squares mean ratio: 1.77 · 95% CI 1.30 to 2.40
  • Treatment Given to Arm Region vs Treatment Given to Abdomen (6 mm) · Geometric least squares mean ratio: 1.91 · 95% CI 1.42 to 2.59
  • Treatment Given to Arm Region vs Treatment Given to Abdomen (9 mm) · Geometric least squares mean ratio: 1.84 · 95% CI 1.37 to 2.49
  • Treatment Given to Arm Region vs Treatment Given to Buttock · Geometric least squares mean ratio: 1.42 · 95% CI 1.05 to 1.92
  • Treatment Given to Thigh vs Treatment Given to Abdomen (6 mm) · Geometric least squares mean ratio: 1.08 · 95% CI 0.80 to 1.46
  • Treatment Given to Thigh vs Treatment Given to Abdomen (9 mm) · Geometric least squares mean ratio: 1.04 · 95% CI 0.77 to 1.41
  • Treatment Given to Thigh vs Treatment Given to Buttock · Geometric least squares mean ratio: 0.80 · 95% CI 0.59 to 1.08
  • Treatment Given to Abdomen (6 mm) vs Treatment Given to Abdomen (9 mm) · Geometric least squares mean ratio: 0.96 · 95% CI 0.72 to 1.30
  • Treatment Given to Abdomen (6 mm) vs Treatment Given to Buttock · Geometric least squares mean ratio: 0.74 · 95% CI 0.55 to 1.00
  • Treatment Given to Abdomen (9 mm) vs Treatment Given to Buttock · Geometric least squares mean ratio: 0.77 · 95% CI 0.57 to 1.04
  • Treatment Given to Arm Region vs Treatment Given to Thigh · Geometric least squares mean ratio: 1.49 · 95% CI 1.09 to 2.02
  • Treatment Given to Arm Region vs Treatment Given to Abdomen (6 mm) · Geometric least squares mean ratio: 1.68 · 95% CI 1.25 to 2.28
  • Treatment Given to Arm Region vs Treatment Given to Abdomen (9 mm) · Geometric least squares mean ratio: 1.84 · 95% CI 1.36 to 2.48
  • Treatment Given to Arm Region vs Treatment Given to Buttock · Geometric least squares mean ratio: 1.16 · 95% CI 0.85 to 1.56
  • Treatment Given to Thigh vs Treatment Given to Abdomen (6 mm) · Geometric least squares mean ratio: 1.13 · 95% CI 0.83 to 1.54
  • Treatment Given to Thigh vs Treatment Given to Abdomen (9 mm) · Geometric least squares mean ratio: 1.24 · 95% CI 0.91 to 1.68
  • Treatment Given to Thigh vs Treatment Given to Buttock · Geometric least squares mean ratio: 0.78 · 95% CI 0.57 to 1.05
  • Treatment Given to Abdomen (6 mm) vs Treatment Given to Abdomen (9 mm) · Geometric least squares mean ratio: 1.09 · 95% CI 0.81 to 1.47
  • Treatment Given to Abdomen (6 mm) vs Treatment Given to Buttock · Geometric least squares mean ratio: 0.69 · 95% CI 0.51 to 0.93
  • Treatment Given to Abdomen (9 mm) vs Treatment Given to Buttock · Geometric least squares mean ratio: 0.63 · 95% CI 0.47 to 0.85
  • Treatment Given to Arm Region vs Treatment Given to Thigh · Geometric least squares mean ratio: 1.49 · 95% CI 1.10 to 2.03
  • Treatment Given to Arm Region vs Treatment Given to Abdomen (6 mm) · Geometric least squares mean ratio: 1.96 · 95% CI 1.45 to 2.65
  • Treatment Given to Arm Region vs Treatment Given to Abdomen (9 mm) · Geometric least squares mean ratio: 2.03 · 95% CI 1.50 to 2.74
  • Treatment Given to Arm Region vs Treatment Given to Buttock · Geometric least squares mean ratio: 1.25 · 95% CI 0.93 to 1.69
  • Treatment Given to Thigh vs Treatment Given to Abdomen (6 mm) · Geometric least squares mean ratio: 1.31 · 95% CI 0.97 to 1.78
  • Treatment Given to Thigh vs Treatment Given to Abdomen (9 mm) · Geometric least squares mean ratio: 1.36 · 95% CI 1.01 to 1.84
  • Treatment Given to Thigh vs Treatment Given to Buttock · Geometric least squares mean ratio: 0.84 · 95% CI 0.62 to 1.14
  • Treatment Given to Abdomen (6 mm) vs Treatment Given to Abdomen (9 mm) · Geometric least squares mean ratio: 1.04 · 95% CI 0.77 to 1.40
  • Treatment Given to Abdomen (6 mm) vs Treatment Given to Buttock · Geometric least squares mean ratio: 0.64 · 95% CI 0.47 to 0.86
  • Treatment Given to Abdomen (9 mm) vs Treatment Given to Buttock · Geometric least squares mean ratio: 0.62 · 95% CI 0.46 to 0.83

Adverse events

Collected over Up to 9 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Given to Arm Region0/40 (0%)0/40 (0%)5/40 (12.5%)
Treatment Given to Thigh0/40 (0%)0/40 (0%)9/40 (22.5%)
Treatment Given to Abdomen (6 mm)0/40 (0%)0/40 (0%)4/40 (10%)
Treatment Given to Abdomen (9 mm)0/40 (0%)0/40 (0%)4/40 (10%)
Treatment Given to Buttock0/40 (0%)0/40 (0%)3/40 (7.5%)
Most frequent other events
Most frequent other events
EventTreatment Given to Arm RegionTreatment Given to ThighTreatment Given to Abdomen (6 mm)Treatment Given to Abdomen (9 mm)Treatment Given to Buttock
Infusion site reactionGeneral disorders5/409/404/404/403/40

Baseline characteristics

All participants who received at least one Infusion.

Age, Continuous
Age, Continuous(years)Overall
Mean40.5 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)Overall
Female10
Male30
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White40
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Overall
Germany40
08

Study locations

2 sites
  • Profil Institut für Stoffwechselforschung
    Neuss, Nordrhein-Westfalen 41460, Germany
  • Profil Mainz
    Mainz, 55116, Germany
09

References and documents

Publications

  • Ignaut D, Fukuda T, Bandi R, Ermer M, Stoffel MS, Zijlstra E, Paavola C. An Investigation Into Local Infusion Site Pain After Infusion of Ultra Rapid Lispro Excipients Across Sites and Depths. J Diabetes Sci Technol. 2024 Jul;18(4):920-929. doi: 10.1177/19322968221135217. Epub 2022 Nov 3. PubMed 36326260 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Dec 2021, 1 month.

Results were first posted in Oct 2023, 1 year 9 months after primary completion.

Of 97 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 1 month is below that.

Counting every sponsor, half of 152 studies reached it within 12 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2021
First posted
Oct 5, 2021
StartActual
Oct 22, 2021
Primary completionActual
Dec 6, 2021
CompletionActual
Dec 6, 2021
Results first posted
Oct 4, 2023
Last update
Oct 4, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05067270
Responsible party
Sponsor
First posted
Oct 5, 2021
Start date
Oct 22, 2021
Primary completion
Dec 6, 2021
Completion
Dec 6, 2021
Results posted
Oct 4, 2023
Last update
Oct 4, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sodium Citrate · Treprostinil · Magnesium Chloride

Start the discussion